Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0598934 (
tumor growth
)
58,965
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Growing evidence indicates that microRNAs are involved in tumorigenesis and progression of hepatocellular carcinoma (HCC). However, the functional mechanisms of miR-205 in HCC remain largely unknown. Here, we demonstrate that miR-205 expression was significantly down-regulated in HCC tissues and cell lines and was correlated with metastatic pathologic features and shorter disease-free and overall survival. Overexpression of miR-205 dramatically inhibited HCC cell proliferation, apoptosis, migration, invasion, epithelial-mesenchymal transition (EMT) in vitro, and
tumor growth
in vivo. We subsequently identified
semaphorin 4C
(
SEMA4C
) as a novel target of miR-205. Furthermore, high expression levels of
SEMA4C
were frequently found in HCC tissues and were associated with poor prognosis. Ectopic expression of
SEMA4C
restored the suppressive effect of overexpressed miR-205 on migration, invasion, and EMT. Taken together, our findings provide new insight into the critical role of miR-205 in regulating
tumor growth
, invasion, and EMT of HCC, suggesting miR-205 may serve as a promising therapeutic target and novel prognostic indicator for patients with HCC.-Lu, J., Lin, Y., Li, F., Ye, H., Zhou, R., Jin, Y., Li, B., Xiong, X., Cheng, N. MiR-205 suppresses
tumor growth
, invasion and epithelial-mesenchymal transition by targeting
SEMA4C
in hepatocellular carcinoma.
...
PMID:MiR-205 suppresses tumor growth, invasion, and epithelial-mesenchymal transition by targeting SEMA4C in hepatocellular carcinoma. 2979 89
Semaphorins, specifically type IV, are important regulators of axonal guidance and have been increasingly implicated in poor prognoses in a number of different solid cancers. In conjunction with their cognate PLXNB family receptors, type IV members have been increasingly shown to mediate oncogenic functions necessary for tumor development and malignant spread. In this study, we investigated the role of
semaphorin 4C
(
SEMA4C
) in osteosarcoma growth, progression, and metastasis. We investigated the expression and localization of
SEMA4C
in primary osteosarcoma patient tissues and its tumorigenic functions in these malignancies. We demonstrate that overexpression of
SEMA4C
promotes properties of cellular transformation, while RNAi knockdown of
SEMA4C
promotes adhesion and reduces cellular proliferation, colony formation, migration, wound healing,
tumor growth
, and lung metastasis. These phenotypic changes were accompanied by reductions in activated AKT signaling, G1 cell cycle delay, and decreases in expression of mesenchymal marker genes SNAI1, SNAI2, and TWIST1. Lastly, monoclonal antibody blockade of
SEMA4C
in vitro mirrored that of the genetic studies. Together, our results indicate a multi-dimensional oncogenic role for
SEMA4C
in metastatic osteosarcoma and more importantly that
SEMA4C
has actionable clinical potential.
...
PMID:SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis. 3158 36